Novel compounds for the treatment of varicella–zoster virus infections

Bibliography

• ARVIN AM: Varicella-zoster virus. Clin . Microbiol Rev (1996) 9:361–81.
   PubMed Web of Science ®Google Scholar
• COHEN JI, BRUNELL PA, STRAUS SE, KRAUSE PR.: Recent advances in varicella-zoster virus infection. Ann. Intern. Med. (1999) 130:922–932.
   Google Scholar
• AEBI C, AHMED A, RAMILO 0: Bacterial complications of primary varicella in children. Clin. Infect. Dis. (1996) 23:698–705.
   PubMed Web of Science ®Google Scholar
• GNANN JW: Varicella-zoster virus: atypical presentations and unusual complications. J . Infect. Dis. (2002) 186\(Supp1.1):591–98.
   Google Scholar
• ENDERS G, MILLER E, CRADOCK -WATSON J, BOLLEY I, RIDEHALGH M: Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet (1994) 343:1548–1551.
   PubMed Web of Science ®Google Scholar
• SNOECK R, ANDREI G, DE CLERCQ E Novel agents for the therapy of varicella-zoster virus infections. Expert Opin. Investig. Drugs (2000) 9:1743–51.
   PubMed Web of Science ®Google Scholar
• PROBER CG, GERSHON AA, GROSE C, MCCRACKEN GH JR, NELSON JD: Consensus: varicella-zoster infections in pregnancy and the perinatal period. Pediatr. Infect. Dis. J. (1990) 9:865–869.
   PubMed Web of Science ®Google Scholar
• TENSER RB: Herpes zoster infection and post-herpetic neuralgia. Curc Neurol Neurosci. Rep. (2001) 1:526–532.
   PubMedGoogle Scholar
• KOST RG, STRAUS SE: Post-herpetic neuralgia-pathogenesis, treatment, and prevention. N Engl. I Med. (1996) 335:32–42.
   PubMed Web of Science ®Google Scholar
• WOOD MJ: How to measure and reduce the burden of zoster-associated pain. Scand. Infect. Dis. (1996) 100(Suppl.):55–58.
   Google Scholar
• WOOD MJ: How should we measure pain in herpes zoster? Neurology (1995) 45:S61–62.
   PubMed Web of Science ®Google Scholar
• TAYLOR CE, SVILAND L, PEARSON AD et al.: Virus infections in bone marrow transplant recipients; a three-year prospectus study. I. Clin. Pathol (1990) 43:633–637.
   PubMed Web of Science ®Google Scholar
• TAPPERO JW, PERKINS BA, WENGER JD, BERGER TG: Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus. Clin. Microbiol Rev (1995) 8:440–450.
   PubMed Web of Science ®Google Scholar
• ALLIEGRO MB, DORRUCCI M, PEZZOTTI P et al.: Herpes zoster and progression to AIDS in a cohort of individuals who seroconverted to human immunodeficiency virus. Italian HIV serovconversion study. Clin. Infect. Dis. (1996) 23:990–995.
   PubMed Web of Science ®Google Scholar
• SMITH JB, FENSKE NA: Herpes zoster and internal malignancy. South Med. I (1995) 88:1089–1092.
   PubMed Web of Science ®Google Scholar
• WINGARD JR: Management of infectious complications of bone marrow transplantation. Oncology (Huntingt) (1990) 4:69–82.
   PubMedGoogle Scholar
• DRUCKER JL, SMILEY L: Herpesviruses. In: Zinsser Microbiology 20th Edition. Joklik WK, Willett HP, Amos DB, Wilfert CM (Eds), Appleton & Lange, Connecticut, USA (1992):959–961.
   Google Scholar
• GROSS G, SCHOFER H, WASSILEW S et al.: Herpes zoster guideline of the German Dermatology Society (DDG). .1 Clin. Virol (2003) 26:277–289.
   Google Scholar
• CHARTRAND SA: Varicella vaccine. Pediatr. Clin. North Ain. (2000) 47:373–394.
   PubMed Web of Science ®Google Scholar
• CENTER FOR DISEASE CONTROL: Morbidity and mortality weekly report. (2002):51.
   Google Scholar
• BREUER J: Vaccination to prevent varicellaand shingles. J. Clin. Pathol (2001) 54:743–747.
   PubMed Web of Science ®Google Scholar
• LEVIN MJ, BARBER D, GOLDBLATT E et al.: Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. .1 Infect. Dis. (1998) 178\(Supp1.1):S109–S112.
   Google Scholar
• EDMUNDS WJ, BRISSON M: The effect of vaccination on the epidemiology of varicella-zoster virus. J. Infect. (2002) 44:211–219.
   PubMed Web of Science ®Google Scholar
• BRISSON M, GAY NJ, EDMUNDS WJ et al.: Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine (2002) 20:2500–2507.
   PubMed Web of Science ®Google Scholar
• LARUSSA P, STEINBERG S, MEURICE F et al.: Transmission of vaccine strain varicella-zoster virus from a healthy adult with vaccine-associated rash to susceptible household contacts. J. Infect. Dis. (1997) 176:1072–1075.
   PubMed Web of Science ®Google Scholar
• BRUNELL PA, ARGAW T: Chickenpoxattributable to a vaccine virus contracted from a vaccine with zoster. Pediatrics (2000) 106:E28.
   Web of Science ®Google Scholar
• UEBE B, SAUERBREI A, BURDACH S, HORNEFF G: Herpes zoster by reactivated vaccine varicella zoster virus in a healthy child. Eur.j Pediatr. (2002) 161:442–444.
   PubMed Web of Science ®Google Scholar
• LEVY 0, ORANGE JS, HIBBERD Petal.:Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. I Infect. Dis. (2003) 188:948–953.
   Google Scholar
• LEVIN MJ, DAHL KM, WEINBERG A, GILLER R, PATEL A, KRAUSE PR: Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. j Infect. Dis. (2003) 188:954–959.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: Antiviral drugs: current state of the art. Clin. Viral. (2001) 22:73–89.
   PubMed Web of Science ®Google Scholar
• ENRIGHT AM, PROBER C: Antiviral therapy in children with varicella-zoster virus and herpes simplex virus infections. Herpes (2003) 10:32–37.
   PubMedGoogle Scholar
• VAJPAYEE M, MALHOTRA N: Antiviral drugs against herpes infections. Indian Phannacol (2000) 32:330–338.
   Google Scholar
• SNOECK R, ANDREI G, DE CLERCQ E: Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment. Drugs (1999) 57:187–206.
   PubMed Web of Science ®Google Scholar
• WASSILEW SW, WUTZLER P: Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. Antiviral Res. (2003) 59:49–56.
   PubMed Web of Science ®Google Scholar
• WASSILEW SW, WUTZLER P: Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on post-herpetic neuralgia. Antiviral Res. (2003) 59:57–60.
   PubMed Web of Science ®Google Scholar
• JOHNSON RW: Herpes zoster in the immunocompetent patient: management of post-herpetic neuralgia. Herpes (2003) 10:38–45.
   PubMedGoogle Scholar
• HAS WGAWA T, KUROKAWA M, YUKAWA TA, HORII M, SHIRAKI K: Inhibitory action of acyclovir (ACV) and penciclovir (PCV) on plaque formation and Partial cross-resistance of ACV-resistant varicella-zoster virus to PCV Antiviral Res. (1995) 27:271–279.
   Google Scholar
• IDA M, KAGEYAMA S, SATO H etal.: Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants. Antiviral Res. (1999) 40:155–66.
   Google Scholar
• IDA M, KAGEYAMA S, SATO et al: Characterization of acyclovir susceptibility and genetic stability of varicella-zoster viruses isolated during acyclovir therapy. .1. Dermatol Sci. (2000) 23:63–72.
   PubMed Web of Science ®Google Scholar
• GILBERT C, BESTMAN-SMITH J, BOIVIN G: Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Update (2002) 5:88–114.
   PubMed Web of Science ®Google Scholar
• VISALLI RJ, VAN ZEIJL M: DNA encapsidation as a target for anti-herpesvirus drug therapy. Antiviral Res. (2003) 59:73–87.
   PubMed Web of Science ®Google Scholar
• ACHESON DW, LEEN CL, TARIQ WU, MANDAL BK: Severe and recurrent varicella-zoster virus infection in a patient with the acquired immune deficiency syndrome. .1 Infect. (1988) 16:193–197.
   PubMed Web of Science ®Google Scholar
• SAFRIN S, BERGER TG, GILSON I etal.: Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann. Intern. Med. (1991) 115:19–21.
   Google Scholar
• VISSE B, DUMONT B, HURAUX et al: Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS. .1. Infect. Dis. (1998) 178\(Supp1.1):S55–S57.
   Google Scholar
• DE CLERCQ E: Biochemical aspects of the selective antiherpes activity of nucleoside analogues. Biochem. Pharmacol (1984) 33:2159–2169.
   PubMed Web of Science ®Google Scholar
• KIMBERLIN DW: Acylcovir derivatives and other new antiviral agents. Sem. Ped. Infect. Dis. (2001) 12:224–234.
   Google Scholar
• NAESENS L, DE CLERCQ E: Recent developments in herpesvirus therapy. Herpes (2001) 8:12–16.
   PubMedGoogle Scholar
• ERIKSSON B, OBERG B, WAHREN B: Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus and cellular origin. Biochim. Biophys. Acta. (1982) 696:115–123.
   PubMed Web of Science ®Google Scholar
• ELION GB: The biochemistry and mechanism of action of acyclovir. .1. Antimicrob. Chemother: (1983) 12 (Suppl.B):9–17.
   Google Scholar
• FRANK KB, CHIOU JF, CHENG YC: Interaction of DNA polymerase and nucleotide analog triphosphates. Adv. Enzyme Regal (1985) 24:377–384.
   PubMedGoogle Scholar
• WHITLEY RJ: Sorivudine: a promising drug for the treatment of varicella-zoster virus infection. Neurology(1995) 45:S73–S75.
   Web of Science ®Google Scholar
• DE CLERCQ E, WALKER RT: Synthesis and antiviral properties of 5-vinyl-pyrimidine nucleoside analogs. Pharmacol. Ther: (1984) 26:1–44.
   Google Scholar
• WUTZLER P, DE CLERCQ E, WUTKE K, FARBER I: Oral brivudin versus intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial. I. Med. Virol (1995) 46:252–257.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E, DESCAMPS J, DE SOMER P et al.: (E)-5-(2-Bromoviny1)-2'-deoxyuridine: a potent and selective anti-herpes agent. Proc. Nati Acad. Sci. USA (1979) 76:2947–2951.
   Google Scholar
• DE CLERCQ E: Antiviral activity of nucleoside analogues: the BVDU connection. In: Recent advances M nucleosides: chemistry and chemotherapy Chu CK (Ed.), Elsevier Science, New York, USA (2002):433–454.
   Google Scholar
• DE CLERCQ E: In search for a selective antiviral chemotherapy. Clin. Microbial. Rev (1997) 10:674–693.
   PubMed Web of Science ®Google Scholar
• PAHVVA S, BIRON K, LIM W et al: Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA (1988) 260:2879–2882.
   PubMed Web of Science ®Google Scholar
• SAINT-LEGER E, CAUMES E, BRETON G et al: Clinical and virologic characterization of acyclovir-resistant varicella-zoster viruses isolated from 11 patients with acquired immunodeficiency syndrome. Gin. Infect. Dis. (2001) 33:2061–2067.
   PubMed Web of Science ®Google Scholar
• MORFIN F, THOUVENOT D, DE TURENNE-TESSIER M et al: Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir. Antimicrob. Agents Chemother. (1999) 43:2412–2416.
   PubMed Web of Science ®Google Scholar
• BOIVIN G, EDELMAN CK, PEDNEAULT L, TALARICO CL, BIRON KK, BALFOUR HH JR: Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. I Infecti. Dis. (1994) 170:68–75.
   Google Scholar
• TALARICO CL, PHELPS WC, BIRON KK: Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS. Vire/ (1993) 67:1024–1033.
   PubMed Web of Science ®Google Scholar
• FILLET AM, DUMONT B, CAUMES E et al.: Acycolvir-resistant varicella-zoster virus: phenotypic and genetic characterization. I Med. Virol. (1998) 55:250–254.
   PubMed Web of Science ®Google Scholar
• NEYTS J, DE CLERCQ E: Mechanism of action of acyclic nucleoside phosphonates against herpesvirus replication. Biochem. Pharmacol (1994) 47:39–41.
   PubMed Web of Science ®Google Scholar
• CIHLAR T, CHEN MS: Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Ma Pharmacol. (1996) 50:1502–1510.
   PubMed Web of Science ®Google Scholar
• CRUMPACKER CS: Mechanism of action of foscarnet against viral polymerases. Am. I. Med. (1992) 92:3S–7S.
   Google Scholar
• DERAY G, MARTINEZ F, KATLAMA C et al.: Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am. .1. Nephrol (1989) 9:316–321.
   Google Scholar
• SJOVALL J, KARLSSON A, OGENSTAD S, SANDSTROM E, SAARIMAKI M: Pharmacokentics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. Clin. Pharmacol Ther: (1988) 44:65–73.
   PubMed Web of Science ®Google Scholar
• WAGSTAFF AJ, BRYSON HM: Foscarnet: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs (1994) 48:199–226.
   PubMed Web of Science ®Google Scholar
• WATHEN MW: Non-nucleoside inhibitorsof herpesviruses. Rev Med. Virol (2002) 12:167–178.
   PubMed Web of Science ®Google Scholar
• MCGUIGAN C, BARUCKI H, BLEWETT S et al: Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. I Med. Chem. (2000) 43:4993–4997.
   PubMed Web of Science ®Google Scholar
• MCGUIGAN C, BRANCALE A, BARUCKI H et al.: Furano pyrimidines as novel potent and selective anti-VZV agents. Antiviral Chem. Chemother. (2001) 12:77–89.
   PubMed Web of Science ®Google Scholar
• BALZARINI I, MCGUIGAN C: Bicyclic pyrimidine nucleoside analogues (BCNAs) as highly selective and potent inhibitors of varicella-zoster virus replication. Antimicrob . Chemother. (2002) 50:5–9.
   Google Scholar
• SIENAERT R, NAESENS L, BRANCALE A, DE CLERCQ E, MCGUIGAN C, BALZARINI I: Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Md. Pharm. (2002) 61:249–254.
   PubMed Web of Science ®Google Scholar
• BALZARINI J, SIENAERT R, LIEKENS S et al.: Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Pharm. (2002) 61:1140–1145.
   Web of Science ®Google Scholar
• DIASIO RB: Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase. Br. Clin. Phannacol (1998) 46:1–4.
   PubMed Web of Science ®Google Scholar
• OKUDA H, OGURA K, KATA A et al.: A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug with oral 5-fluorouracil prodrugs. Pharmacol Exp. Then (1998) 287:791–799.
   PubMed Web of Science ®Google Scholar
• HOLY A, VOTRUBA I, MASOJIDKOVA M et al: 6- [2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity. Med. Chem. (2002) 45:1918–1929.
   Web of Science ®Google Scholar
• BRIDEAU RJ, KNECHTEL ML, HUANG A et al: Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses. Antiviral Res. (2002) 54:19–28.
   PubMed Web of Science ®Google Scholar
• KNECHTEL ML, HUANG A, VAILLANCOURT VA, BRIDEAU RI: Inhibition of clinical isolates of human cytomegalovirus and varicella zoster virus by PNU-183792, a 4-oxo-dihydroquinoline. Med. Viral. (2002) 68:234–236.
   PubMed Web of Science ®Google Scholar
• OIEN NL, BRIDEAU RI, HOPKINS TA et al.: Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors. Andmicrob . Agents Chemother. (2002) 46:724–730.
   PubMed Web of Science ®Google Scholar
• TUCKER IA, CLAYTON TL, CHIDESTER CG et al.: Structure-activity relationships of acyloxyamidine cytomegalovirus DNA polymerase inhibitors. Bioorg. Med. Chem. (2000) 8:601–615.
   PubMed Web of Science ®Google Scholar
• VAILLANCOURT VA, CUDAHY MM, STALEY SA et al.: Naphthalene carboxamides as inhibitors of human cytomegalovirus DNA polymerase. Bioorg. Med. Chem. Let. (2000) 10:2079–2081.
   PubMed Web of Science ®Google Scholar
• THOMSEN DR, OIEN NL, HOPKINS TA et al: Amino acid changes within conserved region III of the herpes simplex virus and human cytomegalovirus DNA polymerases confer resistance to 4-oxo-dihydroquinolines, a novel class of herpesvirus antiviral agents. Viral . (2003) 77:1868–1876.
   PubMed Web of Science ®Google Scholar
• VAN ZEIJL M, FAIRHURST J, JONES TR et al.: Novel class of thiourea compounds that inhibit herpes simplex virus Type 1 DNA cleavage and encapsidation: resistance maps to the UL6 gene.J Virol (2000) 74:9054–9061.
   PubMed Web of Science ®Google Scholar
• VISALLI RI, FAIRHURST J, SRINIVAS S et al.: Identification of small molecule compounds that selectively inhibit varicella-zoster virus replication. J. Vim/. (2003) 77:2349–2358.
   Google Scholar
• BROWN IC, MCVOY MA, HOMA FL: Packaging DNA into herpesvirus capsids. In: Structure-function relationships of human pathogenic viruses. Holzenburg, Bogner (Eds), Kluwer academic/Plenum, New York, USA. (2002):111–153.
   Google Scholar
• NEWCOMB WW, BROWN IC: Inhibition of herpessimplex virus replication by WAY-150138: assembly of capsids depleted of the portal and terminase proteins involved in DNA encapsidation. .1. Virol (2002) 76:10084–10088.
   PubMed Web of Science ®Google Scholar
• NEWCOMB WW, JUHAS RM, THOMSEN DR et al.: The UL6 gene product forms the portal for entry of DNA into the herpessimplex virus capsid. I Vim/. (2001) 75:10923–10932.
   Google Scholar
• BETZ UA, FISCHER R, KLEYMANN G, HENDRIX M, RUBSAMEN-WAIGMANN H et al.: Potent in vivo antiviral activity of the herpessimplex virus primase-helicase inhibitor BAY-571293. Antimicrob. Agents. Chemother. (2002) 46:1766–1772.
   PubMed Web of Science ®Google Scholar
• KLEYMANN G, FISCHER R, BETZ UA et al.: New helicase-primase inhibitors as drug candidates for the treatment of herpessimplex disease. Nat. Med. (2002) 8:392–398.
   PubMed Web of Science ®Google Scholar
• CRUTE II, GRYGON CA, HARGRAVE KD et al.: Herpessimplex virus helicase-primase inhibitors are active in animal models of human disease. Nat. Med. (2002) 8:386–391.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo [2,3-4yrimidine nucleoside analogues. Med . Res. Rev (2003) 23:253–274.
   PubMed Web of Science ®Google Scholar